Purpose: To assess the efficacy and tolerance of the vinorelbine/cisplatin combination in non-small cell lung cancer patients pre-treated with a taxane-based regimen.
Patients And Methods: Among the 32 enrolled patients, 28 (87.5%) had a PS (WHO) of 0-1 and 13 (40.